Latest:
Expanding Treatment Options for HER2+ Breast Cancer
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Ravi A. Chandra, MD, PhD
Latest:
Recognizing the Role of Bias in Patient Decision Making
Doctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.
Ravindra Uppaluri, MD, PhD
Latest:
Dr Uppaluri on the Implications of the FDA Approval of Perioperative Pembrolizumab in Resectable, Locally Advanced HNSCC
Ravindra Uppaluri, MD, PhD, discusses the FDA approval of pembrolizumab in the neoadjuvant and adjuvant setting for resectable, locally advanced HNSCC.
Rebecca Dent, MD, MSc, FRCP
Rebecca Dent, MD, MSc, FRCP, is deputy chief executive officer (clinical) and a senior consultant at the National Cancer Centre Singapore
Latest:
Dr Dent on the Potential Role of Dato-DXd for Immunotherapy-Ineligible TNBC
Rebecca Dent, MD, MSc, FRCP, discussed the future implications of data with first-line Dato-DXd in locally recurrent inoperable or metastatic TNBC.
Reed D. Gelzer, MD, MPH, CHCC
Latest:
The EAR Party's End
Electronic Health Record (EHR) systems hold great promise. However, like many new technologies, the difficulty of achieving EHRs' promise has been vastly underestimated, as have the risks. The current national initiatives pushing for widespread EHR implementation may be leading us into an unmapped minefield.